Search Results 161-170 of 13180 for Tyrosine

  1. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab Monotherapy In Participants With Select B-Cell Malignancies (MorningSun) - Mayo Clinic

    a Bruton's tyrosine kinase (BTK) inhibitor. - Adequate renal function. - Adverse events from prior anti-cancer therapy resolved to Grade ≤ 1. Inclusion ...

  2. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  3. A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer - Mayo Clinic

    ... tyrosine kinase (ROS1) fusions. Encephalitis, meningitis, or uncontrolled seizures in the year prior to randomization. History of interstitial lung disease ...

  4. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  5. A Study to Assess AC220 Given in Combination with Induction and Consolidation Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) - Mayo Clinic

    Either positive or negative FMS-like tyrosine kinase - internal tandem duplication (FLT3-ITD) mutation status; An Eastern Cooperative Oncology Group (ECOG) ...

  6. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  7. Hematology - Clinical trials

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  8. Inotuzumab Ozogamicin In Treating Younger Patients With Relapsed Or Refractory CD22 Positive B Acute Lymphoblastic Leukemia - Mayo Clinic

    ... tyrosine kinase inhibitors (TKIs). Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy, defined as resolution of ...

  9. Hematology - Clinical trials

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  10. Study Of Efficacy And Safety Of CTL019 In Adult ALL Patients - Mayo Clinic

    Short-acting drugs(e.g tyrosine kinase inhibitors, ibrutinib and hydroxyurea) must not be given within a 72 hour window of the leukapheresis procedure.